Since many patients with a HR+, HER2- early breast cancer do not benefit from an adjuvant CT, there is a need to have a molecular rationale for identifying patients who can benefit from CT, as well those for whom CT would not add significant clinical benefit. Here, HR is linked to breast cancer.